Your Input:
|
||||
DRD4 | dopamine receptor D4 (419 aa) | |||
BDKRB1 | bradykinin receptor B1; This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation (353 aa) | |||
C5 | complement component 5; Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled (1676 aa) | |||
PPY | pancreatic polypeptide; Pancreatic hormone is synthesized in pancreatic islets of Langerhans and acts as a regulator of pancreatic and gastrointestinal functions (95 aa) | |||
GRM6 | glutamate receptor, metabotropic 6; Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity (877 aa) | |||
NPY | neuropeptide Y; NPY is implicated in the control of feeding and in secretion of gonadotrophin-release hormone (97 aa) | |||
C3 | complement component 3; C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates (1663 aa) | |||
S1PR4 | sphingosine-1-phosphate receptor 4; Receptor for the lysosphingolipid sphingosine 1- phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. May be involved in cell migration processes that are specific for lymphocytes (384 aa) | |||
CCR7 | chemokine (C-C motif) receptor 7; Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions (378 aa) | |||
TAS2R3 | taste receptor, type 2, member 3; Gustducin-coupled receptor implicated in the perception of bitter compounds in the oral cavity and the gastrointestinal tract. Signals through PLCB2 and the calcium-regulated cation channel TRPM5 (316 aa) | |||
MCHR1 | melanin-concentrating hormone receptor 1; Receptor for melanin-concentrating hormone, coupled to both G proteins that inhibit adenylyl cyclase and G proteins that activate phosphoinositide hydrolysis (422 aa) | |||
GALR3 | galanin receptor 3; Receptor for the hormone galanin (368 aa) | |||
HRH4 | histamine receptor H4; The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist) (390 aa) | |||
APLNR | apelin receptor; Receptor for apelin coupled to G proteins that inhibit adenylate cyclase activity. Alternative coreceptor with CD4 for HIV-1 infection; may be involved in the development of AIDS dementia (380 aa) | |||
NMU | neuromedin U; Stimulates muscle contractions of specific regions of the gastrointestinal tract. In humans, NmU stimulates contractions of the ileum and urinary bladder (174 aa) | |||
POMC | proopiomelanocortin; ACTH stimulates the adrenal glands to release cortisol (267 aa) | |||
KNG1 | kininogen 1; (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects- (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation [...] (644 aa) | |||
MCHR2 | melanin-concentrating hormone receptor 2; Receptor for melanin-concentrating hormone, coupled to G proteins that activate phosphoinositide hydrolysis (340 aa) | |||
CXCL13 | chemokine (C-X-C motif) ligand 13; Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B- lymphocytes. Binds to BLR1/CXCR5 (109 aa) | |||
HTR5A | 5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled; This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins (357 aa) | |||
CXCR5 | chemokine (C-X-C motif) receptor 5; Cytokine receptor that binds to B-lymphocyte chemoattractant (BLC). Involved in B-cell migration into B-cell follicles of spleen and Peyer patches but not into those of mesenteric or peripheral lymph nodes. May have a regulatory function in Burkitt lymphoma (BL) lymphomagenesis and/or B-cell differentiation (372 aa) | |||
CCR2 | chemokine (C-C motif) receptor 2; Receptor for the MCP-1, MCP-3 and MCP-4 chemokines. Transduces a signal by increasing the intracellular calcium ions level. Alternative coreceptor with CD4 for HIV-1 infection (374 aa) | |||
CCR5 | chemokine (C-C motif) receptor 5 (gene/pseudogene) (352 aa) | |||
CCL5 | chemokine (C-C motif) ligand 5; Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. Binds to CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T- cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exh [...] (91 aa) | |||
GNAI1 | guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 (354 aa) | |||
RGS14 | regulator of G-protein signaling 14; Acts as a regulator of G protein signaling (RGS). Modulates G protein alpha subunits nucleotide exchange and hydrolysis activities by functioning either as a GTPase-activating protein (GAP), thereby driving G protein alpha subunits into their inactive GDP-bound form, or as a GDP-dissociation inhibitor (GDI). Confers GDI activity on G(i) alpha subunits GNAI1 and GNAI3, but not G(o) alpha subunit GNAO1 and G(i) alpha subunit GNAI2. Confers GAP activity on G(o) alpha subunit GNAI0 and G(i) alpha subunits GNAI2 and GNAI3. May act as a scaffold integrati [...] (566 aa) |